Avricore Health Inc 6-K, filed Oct 13, 2022
Avricore Health Inc. (AVCRF)
About this 6-K
Avricore Health Inc filed this 6-K on October 13, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2021.
Commission File Number: 000-51848
Avricore Health Inc.
(Exact name of registrant as specified in its charter)
1120-789 West Pender St, Vancouver, BC, V6C 1H2
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): NO
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): NO
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Exhibits
The following exhibits are included in this form 6-K:
| Exhibit No. | Description | Date Released | ||
| 1 | News Release AVRICORE HEALTH CEO HOSTS INVESTOR CALL DECEMBER 15TH | December 9, 2021 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AVRICORE HEALTH INC. | ||
| Date: October 12, 2022 | By | /s/ Kiki Smith |
| Kiki Smith | ||
| Chief Financial Officer | ||
Exhibit 1
AVRICORE HEALTH CEO HOSTS INVESTOR CALL DECEMBER 15TH
VANCOUVER, BRITISH COLUMBIA – December 9, 2021 – AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “AVCR”) will host a year end update and look ahead discussion by the Company’s CEO and key team members.
“We’ve had our best year yet, despite many external factors that created headwinds, and we’re extremely excited to head into 2022.” said Avricore Health CEO, Hector Bremner. “Given that we are well capitalized and have executed several key agreements already, we’re well positioned for growth.”
Call Details:
December 15th, 2021 @ 10:00am PT / 1:00pm ET via Zoom
(Link and access codes shared upon registration)
Agenda:
The 60-minute call agenda will be as follows:
| ● | 10min: Opening Remarks / Team Introductions | |
| ● | 20Min: Overview Presentation and Update | |
| ● | 30Min: Q&A |
To register, please email your contact details (Name, Phone) to: investor@avricorehealth.com. You will receive log-in instructions and access codes prior to the meeting. Also, please feel free to review our most recent investor presentation here: http://www.avricorehealth.com/investment-kit/
About HealthTab™
HealthTab™
is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform
for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results
on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases,
such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial
and viral tests, such as strep and COVID-19.
The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role
in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and
provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention &
management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration
through API.
About Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company’s mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.
Contact:
Avricore Health Inc.
Hector
Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com
Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company’s expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health’s management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore’s public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this statement.